Drug Trials Snapshots: VABYSMO

Why It Matters

VABYSMO offers clinicians an alternative anti‑VEGF therapy that matches aflibercept's efficacy while providing flexible dosing, potentially improving patient adherence and reducing clinic burden.

Key Takeaways

• VABYSMO studied in 2,591 patients across nAMD and DME trials.
• Visual acuity gains matched aflibercept in both disease groups.
• Adverse event rates were comparable between VABYSMO and aflibercept.
• Subgroup analyses showed consistent efficacy across sex, race, age.
• Monthly injections for four months then individualized dosing schedule.

Pulse Analysis

Genentec's VABYSMO entered the ophthalmic market as a dual‑indication anti‑VEGF agent for wet age‑related macular degeneration and diabetic macular edema. The drug’s bispecific design targets both VEGF‑A and angiopoietin‑2, aiming to improve vascular stability in the retina. In the registration program, two nAMD trials (NCT03823287, NCT03823300) and two DME trials (NCT03622580, NCT03622593) enrolled a total of 2,591 participants across more than 300 sites worldwide, reflecting a robust, diverse patient population.

Efficacy data demonstrated that VABYSMO’s mean gain in best‑corrected visual acuity (BCVA) was on par with aflibercept—5.8 to 6.6 ETDRS letters in nAMD and 10.7 to 11.8 letters in DME after one year. The drug’s dosing regimen, consisting of four monthly loading injections followed by individualized intervals guided by retinal imaging, may reduce injection frequency for stable patients. This flexibility aligns with a growing industry trend toward personalized treatment schedules, potentially easing the logistical load on retina specialists and improving patient quality of life.

Safety outcomes were reassuring; common ocular events such as conjunctival hemorrhage, vitreous floaters, and intra‑ocular pressure elevation occurred at similar rates to aflibercept, and no new safety concerns emerged across sex, race, or age subgroups. As the anti‑VEGF market matures, VABYSMO’s comparable efficacy, comparable safety, and adaptable dosing could carve out a meaningful share, especially in practices seeking to balance therapeutic outcomes with operational efficiency. Its performance may also influence future pricing negotiations and formulary placements, shaping the competitive dynamics among biologic eye‑drop alternatives.